Family Medicine Specialists Selects Cardio Diagnostics' Epigenetic-Genetic Tests For Assessing Heart Attack Risk For Its BlueCross BlueShield Patients
Portfolio Pulse from Benzinga Newsdesk
Family Medicine Specialists (FMS) is implementing Cardio Diagnostics Holdings, Inc.'s (NASDAQ:CDIO) solutions to identify patients at risk for coronary heart disease. The initiative will use Cardio Diagnostics' advanced blood-based epigenetic-genetic tests to risk stratify FMS' patient population. FMS will implement Cardio Diagnostics' heart attack risk assessment test, Epi+Gen CHD, in at least 1,200 patients with CHD risk factors with BlueCross BlueShield health plans.
November 07, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardio Diagnostics' partnership with FMS and its implementation of the company's heart disease risk assessment solutions could potentially increase the company's revenue and market presence.
The partnership with FMS and the implementation of Cardio Diagnostics' solutions in FMS' patient population could lead to increased usage and sales of Cardio Diagnostics' products. This could potentially increase the company's revenue and enhance its market presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100